Paper · 39265124

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.

Bardia A and 23 others. J Clin Oncol, 2025. Cited by 178 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. Papers, record 39265124. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39265124

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.; PubMed
Journal: J Clin Oncol; PubMed
Year: 2025; PubMed
Publication types: Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/39265124/; PubMed
DOI: https://doi.org/10.1200/jco.24.00920; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC11771365/; PubMed
The journal: https://conductscience.org/library/journal-index/8309333; PubMed
Citations, by iCite: 178; iCite
Relative citation ratio, by iCite: 45.36, provisional; iCite
Revised in PubMed: 2026-09-23; PubMed

Authors24

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Bardia A	Aditya	https://orcid.org/0000-0003-4885-1157
2	Jhaveri K	Komal	https://orcid.org/0000-0003-0472-1254
3	Im SA	Seock-Ah	https://orcid.org/0000-0002-5396-6533
4	Pernas S	Sonia	https://orcid.org/0000-0002-1485-5080
5	De Laurentiis M	Michelino	https://orcid.org/0000-0001-9009-1572
6	Wang S	Shusen	https://orcid.org/0000-0003-0139-5780
7	Martínez Jañez N	Noelia
8	Borges G	Giuliano
9	Cescon DW	David W	https://orcid.org/0000-0002-1080-0998
10	Hattori M	Masaya	https://orcid.org/0000-0002-0935-9269

1 to 10 of 24Source PubMed

See all 24 authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Breast Neoplasms	Major topic
Erb-b2 Receptor Tyrosine Kinases	Major topic
Antineoplastic Combined Chemotherapy Protocols	Major topic
Immunoconjugates	Major topic
Humans
Female
Middle Aged
Adult
Aged
Receptors, Estrogen
Receptors, Progesterone
Vinorelbine
Capecitabine
Gemcitabine
Progression-Free Survival
Deoxycytidine

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by	Source
P30 CA008748	NCI NIH HHS	United States	P30CA008748	PubMed and NIH	NIH RePORTER
P30 CA016042	NCI NIH HHS	United States	P30CA016042	PubMed	NIH RePORTER

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record
NCT05104866	A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)	Derived from the trial	Yes

Source ClinicalTrials.gov

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References29

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	29,846,104	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.	Arch Pathol Lab Med	2018	https://conductscience.org/library/papers/29846104	PubMed
2	26,000,093	Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications.	Genes Cancer	2015	https://conductscience.org/library/papers/26000093	PubMed
3	37,387,213	TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.	Future Oncol	2024	https://conductscience.org/library/papers/37387213	PubMed
4	34,413,126	Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.	Mol Cancer Ther	2021	https://conductscience.org/library/papers/34413126	PubMed
5	37,526,149	TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.	Future Oncol	2023	https://conductscience.org/library/papers/37526149	PubMed
6	36,027,558	Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.	J Clin Oncol	2022	https://conductscience.org/library/papers/36027558	PubMed
7	32,946,924	Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.	Ann Oncol	2020	https://conductscience.org/library/papers/32946924	PubMed
8	37,256,976	Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.	N Engl J Med	2023	https://conductscience.org/library/papers/37256976	PubMed
9	21,376,385	Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.	Lancet	2011	https://conductscience.org/library/papers/21376385	PubMed
10	34,324,367	Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.	J Clin Oncol	2021	https://conductscience.org/library/papers/34324367	PubMed

1 to 10 of 29

See all 29 references

Cited by137

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 178 citations.

PMID	Title	Journal	Year	In Papers	Source
42,988,817	Antibody-drug conjugates: unpacking toxicity profiles and optimized designs for enhanced safety and antitumor efficacy.	Signal Transduct Target Ther	2026	https://conductscience.org/library/papers/42988817	PubMed
42,964,697	Endocrine resistance in HR+/HER2- breast cancer: molecular mechanisms and emerging therapeutic strategies.	Front Oncol	2026	https://conductscience.org/library/papers/42964697	PubMed
42,943,283	Discovery and Optimization of the Novel Immunotoxins Targeting TROP2 for Cancer Therapy.	Pharmaceuticals (Basel)	2026	https://conductscience.org/library/papers/42943283	PubMed
42,920,907	Molecular and immune-mediated resistance to antibody-drug conjugates in breast cancer.	Front Immunol	2026	https://conductscience.org/library/papers/42920907	PubMed
42,900,402	Antibody-drug conjugates and tumor immunity in breast cancer.	Med Oncol	2026	https://conductscience.org/library/papers/42900402	PubMed
42,882,921	Choosing Between Anti-TROP2 ADCs in Advanced Breast Cancer Without Head-to-Head Evidence: A Practical Evidence-Informed Decision Framework Endorsed by the Polish Society of Clinical Oncology.	Cancers (Basel)	2026	https://conductscience.org/library/papers/42882921	PubMed
42,863,323	Cell-resolved spatial mapping of antibody-drug conjugate targets in breast cancer.	Transl Oncol	2026	https://conductscience.org/library/papers/42863323	PubMed
42,835,399	Antibody-Drug Conjugates in Breast Cancer: Therapeutic-Window Engineering, Tumor Heterogeneity, and Immunotherapy Combinations.	Drug Des Devel Ther	2026	https://conductscience.org/library/papers/42835399	PubMed
42,820,303	Antibody-drug conjugates in breast cancer: redefining targeted therapy.	J Clin Invest	2026	https://conductscience.org/library/papers/42820303	PubMed
42,820,289	Toward targeted therapeutics for lobular breast cancer.	J Clin Invest	2026	https://conductscience.org/library/papers/42820289	PubMed

1 to 10 of 137

See all 137 cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
ERBB2	2,064	PubTator's text mining	https://conductscience.org/library/genes/2064	NCBI Gene
NR4A1	3,164	PubTator's text mining	https://conductscience.org/library/genes/3164	NCBI Gene

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

Drug	ChEMBL ID	The trials list it as	Trials	In Drugs and targets
DATOPOTAMAB DERUXTECAN	CHEMBL4297939	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL4297939

Source ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39265124

GET https://conductscience.org/api/papers/v1/39265124/authors?page=2

API reference For AI assistants